Nitrite (NO 2 -) is assumed to play an important role in regulation of vascular tone as a reservoir of nitric oxide (NO). To examine its physiological contribution, however, a sensitive method is required for determination of the true level of NO 2 -in biological samples. To this end, practical consideration to avoid NO 2 -contamination through the quantification procedure is important. We present here a highly sensitive and accurate method for determining NO 2 -in plasma by improving the HPLC-Griess system with minimal NO 2 -contamination in the samples. The system achieved high sensitivity (detection limit of 2 nM and sensitivity to 1 nM) and complete separation of the NO 2 -signal peak by modifying the system setup and mobile phase. Using this method, we achieved acceptable quantification of low NO 2 -levels in plasma. Deproteinization by ultrafiltration and exposure to atmosphere before measurement were identified as the major sources of NO 2 -contamination during sample processing. We addressed these issues by the use of methanol for deproteinization and gas-tight caps. These countermeasures allowed us to detect small arterio-venous NO 2 -differences in rabbit plasma that may indicate kinetic difference of NO 2 -in a small number of samples (n = 6). This difference became prominent when NO 2 -or a NO releasing agent, NOR1, was intravenously applied. Our results indicate that application of a sensitive method with careful handling is important for accurate determination of NO 2 -and that our method is applicable for further examination of the kinetic features of NO 2 -in vivo. NO 2
) is assumed to play an important role in regulation of vascular tone as a reservoir of nitric oxide (NO). To examine its physiological contribution, however, a sensitive method is required for determination of the true level of NO 2 -in biological samples. To this end, practical consideration to avoid NO 2 -contamination through the quantification procedure is important. We present here a highly sensitive and accurate method for determining NO 2 -in plasma by improving the HPLC-Griess system with minimal NO 2 -contamination in the samples. The system achieved high sensitivity (detection limit of 2 nM and sensitivity to 1 nM) and complete separation of the NO 2 -signal peak by modifying the system setup and mobile phase. Using this method, we achieved acceptable quantification of low NO 2 -levels in plasma. Deproteinization by ultrafiltration and exposure to atmosphere before measurement were identified as the major sources of NO 2 -contamination during sample processing. We addressed these issues by the use of methanol for deproteinization and gas-tight caps. These countermeasures allowed us to detect small arterio-venous NO 2 -differences in rabbit plasma that may indicate kinetic difference of NO 2 -in a small number of samples (n = 6). This difference became prominent when NO 2 -or a NO releasing agent, NOR1, was intravenously applied. Our results indicate that application of a sensitive method with careful handling is important for accurate determination of NO 2 -and that our method is applicable for further examination of the kinetic features of NO 2 -in vivo. NO 2 -measurement; NO 2 -contamination; HPLC-Griess system; arterio-venous differences; biological samples. Tohoku J. Exp. Med., 2008, 215 (1), 1-11. © 2008 Tohoku University Medical Press Nitrite (NO 2 -), a metabolite of nitric oxide (NO), is assumed not only to be a possible index of endothelial NO production, but also to play an important role in regulation of vascular tone as an intrinsic reservoir of nitric oxide (NO). The latter possibility is supported by the fact that nitrite reductase activity of deoxygenated hemoglobin (deoxyHb) catalyzed NO 2 -to form NO (Dejam et al. 2004) . Indeed, several studies have reported a close relationship among changes in endotheliumdependent blood flow, plasma NO 2 -levels (Lauer et al. 2001; Kleinbongard et al. 2003 Kleinbongard et al. , 2006 , Kleinbongard et al. 2003 ) compared with plasma levels of nitrates (NO 3 -) (Ishibashi et al. 2000a; Himeno et al. 2003) , although the measurement may not necessarily be free from contamination. Measurements are therefore required to minimize possible NO 2 -contamination from laboratory ware and the environment to accurately determine the level of this ubiquitous substance in biological samples (Ishibashi et al. 2000a; Himeno et al. 2004 ). Many laboratories have stressed the importance of avoiding contamination in the enhancement of vasodilatory activity of NO 2 -and increased production of NO in the presence of deoxyHb (Cosby et al. 2003; Lundberg and Govoni 2004; Crawford et al. 2006; Grubina et al. 2007; Shiva et al. 2007 ). Investigating these processes requires accurate and highly sensitive methods for quantifying NO 2 -, although improving the sensitivity of such techniques also increases the chance of confounding factors that must be excluded. Plasma NO 2 -level is relatively unaffected by diet or renal function (Lauer et al. 2001 ; Slight modification (changes in concentration of ion pair and NaCl) of the mobile phase prolonged retention time of NO 2 -by about 2 min. This modification is necessary for complete separation of NO 2 -peak from the front breakthrough for accurate quantification of the subject. A: Peak of NO 2 -in standard solution (1 μ M in standard mobile phase, loading volume of 100 μ l) with the standard mobile phase. B: Peak of NO 2 -in human plasma (loading volume of 100 μ l) with the standard mobile phase. Note that overlapping the peak of NO 2 -with the descending part of the breakthrough makes accurate evaluation of the peak difficult. C: Peak of NO 2 -in standard solution (1 μ M in modified mobile phase, loading volume of 100 μ l) with the modified mobile phase. Retention time is prolonged by about 2 min. D: Peak of NO 2 -in human plasma (the same sample subjected in B, loading volume of 100 μ l) with the modified mobile phase. The peak of NO 2 -is clearly independent and accurate evaluation is possible. Dotted lines indicate retention time of NO 2 -in the standard solution and human plasma with standard mobile phase to indicate prolongation of retention time with modified mobile phase. determination of NO 3 - (Ishibashi et al. 2000a; Dejam et al. 2004; Tsikas et al. 2006) . However, publications dealing with NO 2 -measurement in biological samples rarely provide such warnings about sample contamination. The present study sought to clarify the origins and extent of NO 2 -contamination during biological sample handling and to explore countermeasures for eliminating contamination. In addition, we verified the effectiveness of such measures in specific biological applications.
MATERIALS AND METHODS

Measurement of NO
-was quantified using high-performance liquid chromatography (HPLC) on a Griess system (ENO 10 and ENO 20, Eicom, Kyoto). The system consists of a separation column, a flow reactor (with Griess reagent), reduction column, and a 540-nm detector as described elsewhere (Ishibashi et al. 2000b ). The detection limit and sensitivity were both 0.1 μ M for NO 2 -with a loading volume of 10 μ l under the default setup; however, for nanomolar determinations of NO 2 -, we made two modifications. First, the loading volume was increased to 100 μ l and the reduction column was removed. Second, the composition of the mobile phase (Yamada and Nabeshima 1997) was slightly modified (NaCl was reduced to 2 g/L) to prolong NO 2 -retention time and ensure complete separation from the front breakthrough when plasma was subjected to quantification (Fig. 1) . The modification was because an increased injection volume (100 μ l) of sample submerged NO 2 -signal in a larger breakthrough (Fig. 1B) . These changes increased the sensitivity and detection limit for NO 2 -to 1 and 2 nM, respectively ( Fig. 2) .
Human plasma
Human plasma was drawn into a vacuum bloodsampling tube containing a heparin disk (Venoject H050, Terumo, Tokyo) from five healthy volunteers from the laboratory staff of the Department of Pharmacology, Kanazawa Medical University. Each volunteer gave written informed consent prior to blood sampling. The present study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Kanazawa Medical University.
Animal experiments
Japanese white rabbits weighing 2.4-3.5 kg were anesthetized with intravenous sodium pentobarbital (30 mg/kg). Cannulae were inserted into the jugular veins (for drug administration), carotid arteries (for monitoring blood pressure), as well as femoral veins and arteries (for blood sampling). Pulse rate was monitored using a tachometer triggered by arterial pressure pulse wave. Experimental procedures were performed after a stabilization period of 20-60 min. First, baseline control blood samples were collected, then after several minutes for recovery of hemodynamic parameters, 500 nmoles/kg of
nitro-6-methoxy-3-hexenamide (NOR1, an NO donor agent) was injected intravenously (0.1 ml/kg of 5 mM NaNO 2 in saline or 5 mM NOR1 in dimethyl sulfoxide [DMSO] ), and arterial and venous blood samples were withdrawn 30 sec later. A small volume of the initial -was dissolved in modified mobile phase and 100 μ l was loaded into the HPLC-Griess system. Each point represents the mean ± S.E.M. of three measurements. A significant difference from the blank (mobile phase alone) was recognized at 1 nM, although linearity was observed above 2 nM and the difference from 3 nM was statistically significant. To simplify the figure, marks denoting statistical significance were omitted. As the mobile phase itself contains a small, but significant amount of NO 2 -, AUC (area under curve) of each measurement represents the difference from the mean of the blank control (mobile phase).
blood sample (about 0.5 ml) was used to wash the sampling route (including syringe), and was then discarded to avoid possible contamination of subsequent sample. Then, samples of arterial and venous blood (1.5 ml each) were collected. Blood samples were immediately transferred to prewashed microcentrifuge tubes (1.5 ml, QSP, Porex Bio Products Group, Petaluma, CA, USA) each containing a heparin disk (1/4 piece taken from vacuum blood-sampling tubes (Venoject II/VP-H050K, Terumo, Tokyo). Plasma was obtained after centrifugation (1,600 × g for 5 min at 4°C), and then mixed with methanol (1 : 1) and centrifuged (10,000 × g for 10 min at 4°C) to remove proteins. The supernatant was used immediately for NO 2 -analysis in every experiment. These procedures minimized NO 2 -and NO 3 -contamination of the blood samples from laboratory ware and environment. The Ethics Committee of Kanazawa Medical University approved all animal procedures, and animals were treated under conditions set by the "Guiding Principles for the Care and Use of Laboratory Animals (Japanese Pharmacological Society)".
Reagents
NaNO 2 (Wako Pure Chemical Industries, Osaka) was dissolved in saline (Otsuka Pharmaceutical Factory, Tokushima). NOR1 (Dojindo Laboratories, Kumamoto) was dissolved in DMSO (Wako Pure Chemical Industries, Osaka). All other chemicals were of analytical grade and commercially available. Special attention was paid to the water quality, and only pure water (resistance >18.3 Mohm: MILLI-Q SP; Millipore Co., Bedford, MA, USA) was used following confirmation of low levels of contaminating NO 2 -and NO 3 -(< 10 nM).
Statistical analysis
All data were expressed as mean ± S.E.M. Within groups differences were compared by using the paired t-test while differences between two groups were tested by the unpaired t-test. Differences among three or more groups were compared by one-way analysis of variance followed by Fischer's method. Differences were considered significant at a probability value ( p) of less than 0.05.
RESULTS
It is well known that significant NO 3 -contamination of samples could occur during the entire measurement procedure (Ishibashi et al. 2000a) . In this study, we therefore first assessed possible contamination of our samples with NO 2 -.
To simulate human blood-sample processing for NO 2 -determination at nanomolar levels using a butterfly needle, 5 ml of phosphate buffered saline (PBS) was drawn into a vacuum blood-sampling tube containing a heparin disk (Venoject H050, Terumo, Tokyo) and gently agitated by rolling. After centrifugation (1,700 × g, for 5 min at 4°C), 1 ml of the supernatant was transferred to a microcentrifuge tube for preservation at −80°C. A sample of the PBS used for NO 2 -determination (0.5 ml) was immediately transferred to a new microcentrifuge tube without preservation, and was deproteinized by mixing with 0.5 ml of methanol. The solution was vortexed before centrifugation (10,000 × g, for 10 min at 4°C), and the solution (as supernatant) was decanted into another microcentrifuge tube. The solution was then transferred to a sample tube (Gilson, Middleton, WI, USA) from which the analysis aliquot was loaded automatically (Autoinjector 234, Gilson) onto the HPLC-Griess system described above for NO 2 -determination. As shown in Fig. 3 , NO 2 -concentration significantly increased by approximately 23 nM (n = 8) after the handling procedure. To identify the source of the contamination, NO 2 -was also measured at every step of the procedure. The use of vacuum blood-sampling tubes had no effect on NO 2 -concentration. Repeated washing (5 times) of plastic disposable laboratory ware with pure water slightly but significantly (by about 3 nM) reduced NO 2 -contamination throughout the whole procedure. The major source of contamination was the deproteinization step. Methanol treatment (1 : 1) increased NO 2 -concentration by an average of 10 nM (Fig. 4) , indicating that the methanol used contained NO 2 -, and this was confirmed by analysis of methanol alone (NO 2 -concentration of 12.6 ± 1.4 nM; n = 3). This level was also found in methanol from other glass bottles regardless of lot number or duration after opening (data not shown).
In another study, we explored the best way to pretreat plasma to minimize NO 2 -contamination. Ultrafiltration proved unsuitable for this aim; when 1 ml of PBS was ultrafiltered by several different commercially available units, contamination varied from 26 nM to 1,350 nM depending on manufacturer or filter membrane material used (Figs. 4 and 5) . The lowest noise was found with the Centrisart I (Sartrius, Göttingen, Germany), a unique ultrafiltration unit consisting of an outer tube and a sliding inner cylinder fitted with a filter membrane (cut-off of 10 kDa, triacetylcellulose) at the bottom. The test sample was placed between the outer tube and the filter membrane of the inner cylinder. Following centrifugation (1,800 × g for 5 min), the upward filtrate was obtained in the inner cylinder (filtration direction opposite to other common filter units examined). NO 2 -concentration in the PBS significantly increased from 6.4 ± 0.8 nM to 32.7 ± 2.3 nM using this unit (n = 6); this increase was about half of that with common units that use the same membrane material, but with downward filtration (increase by about 60 nM, VS [TAC]; Fig. 5 ). However, the increase was still significantly greater than that associated with methanol treatment (Fig. 4) . Methanol mixing was therefore chosen as the preferred pretreatment of plasma for deproteinization prior to NO 2 -measurement. Unless otherwise mentioned, all laboratory ware was washed 5 times with pure water to minimize not only NO 2 -, but also NO 3 -contamination. Next, we evaluated possible NO 2 -contamination from room air. As shown in Fig. 6 , tubes left open to the environment for only 1 hr showed increased NO 2 -in solution compared to capped tubes, which showed no significant increase within 8 hours regardless of constituents of the gaseous phase in the headspace of the tube: either room air or argon gas. Other possible atmospheric contamination was also examined. The transfer of pure water (about 50 ml) from the tap of the reservoir to a washed beaker (200 ml) set at 1 and 2 m below tended to increase NO 2 -concentration in the solution (10.6 ± 2.5 nM at 1 m below and 11.2 ± 1.8 nM at 2 m below), compared with water expelled directly down the wall of the beaker from the tap (8.5 ± 2.3 nM; n = 6 in each trial), although the difference was not statistically significant. Vigorous sample mixing by vortexing with room air in a microcentrifuge tube (1.5 ml) was another cause for concern. Ten vortexings of -by methanol treatment and ultrafiltration. PBS (Cont) was subjected to methanol treatment (mixed with methanol in volume of 1 : 1, MetHO) or ultrafiltrated by Centrisart I (1 ml, 1,800 × g for 5 min, C-I). **p < 0.01 (n = 6 for each bar). The following ultrafiltration units with a cut-off of 10 kDa were tested: Ultrafree-MC (UF-MC: Millipore Co., Bedford, MA, USA) for small volumes (A: up to 0.4 ml) and Vivaspin (VC: Sartorius, Göttingen, Germany) for large volumes (B: up to 2 ml). All units are of the common type in which the sample is filtered downwards. Control: PBS in a reservoir (before load). Top: PBS (0.4 ml for small volume, and 1 ml for large volume) only loaded into upper unit (loading device). Bottom: PBS (0.4 ml for small volume, and 1 ml for large volume) only loaded into lower unit (collecting device): Ultrafiltrated: PBS ultrafiltrated (0.4 ml for 10 min at 5,000 × g in small units and 1 ml for 10 min at 1,800 × g in large units) after 5 washes of upper (including surface of filter) and lower units. Each unit was used without prewash in pure water unless otherwise stated. Each bar represents results of 6 trials, each using new units. **p < 0.01, compared with the control (Only this difference is indicated in the figure to simplify the graphic presentation). Material of the filter is indicated in parenthesis. TAC, triacetylcellulose; RC, regenerated cellulose; PES, polyethersulfone. PBS (0.5, 1.0, and 1.5 ml) for 30 sec each separated by 30-sec intervals during which the lids were kept open to exchange air of the head space did not increase NO 2 -level significantly in comparison to those not vortexed at all (n = 8 for each trial and for control; data not shown). Increasing the total number of vortex sequences (vortex 30 sec followed by air exchange 30 sec) by 5, 10, and 20 times had no significant effect on NO 2 -levels compared to unvortexed controls (n = 8 in each trial and control; data not shown).
Based on these preliminary experiments, we avoided exposure of samples to the open room air whenever possible. We then applied the described optimizations to processing of biological samples from human and anesthetized rabbits.
First, we quantitatively compared NO 2 -signals from the same human plasma sample under different separation conditions (with default mobile phase or modified mobile phase) because the modified mobile phase showed a NO 2 -signal that was independent of the initial breakthrough (Fig. 1) . The estimated concentration of NO 2 -in human venous plasma with a modified mobile phase (92 ± 33 nM) was significantly ( p < 0.05, n = 5) higher than in samples with a default mobile phase (70 ± 29 nM).
Using this highly sensitive procedure on rabbit plasma, we detected a small (by approximately 93 nM, mean) but significant arterio-venous difference in NO 2 -level under control conditions in a small number of samples (Fig. 7A, n = 6 ). Intravenous injection of NaNO 2 (500 nmoles/kg body weight) significantly increased the plasma NO 2 -levels in both arterial and venous blood ( p < 0.01). The arterio-venous difference became more prominent after the NaNO 2 load; the arterial level was markedly higher than the venous level despite the intravenous injection (Fig. 7B) . Under this condition, there were no significant changes in heart rate (control: 288.2 ± 13.4, NaNO 2 : 288.2 ± 13.6 beats/min) or mean blood pressure (control: Fig. 6 . NO 2 -contamination from room air. Sampling tube for automated sampler (1 ml) with 0.18 ml of PBS (0.1 mM, pH 7.4) was left open to room air or capped with or without flushing the headspace with argon gas. These samples were kept at 4°C for the indicated period and NO 2 -was determined. NO 2 -levels in tubes exposed to room air were significantly higher than in those capped with either room air or argon gas in headspace after 1 h. However, no significant increases were observed in NO 2 -levels in tubes capped with room air at up to 8 hrs. Marks denoting the statistical differences were not presented in the figure to simplify the graphic presentation (n = 4 for each bar).
107.2 ± 4.5, NaNO 2 : 107.3 ± 4.2 mmHg). In another set of tests (n = 5), intravenous injection of NOR1 (500 nmoles/kg) significantly ( p < 0.05) decreased blood pressure by 54.1 ± 1.3 mmHg (control: 102.0 ± 3.1, NOR1: 47.9 ± 2.5 mmHg) without changes in heart rate (control: 312.8 ± 7.6, NOR1: 315.4 ± 9.7 beats/min) after 30 sec. Concomitant increase in arterial NO 2 -concentration by 111 ± 7 nM (control: 201 ± 32, NOR1: 312 ± 36 nM) was significantly ( p < 0.05) greater than in venous NO 2 -concentration by 28 ± 8 nM (control: 179 ± 24, NOR1: 208 ± 25 nM; p < 0.05).
DISCUSSION
In this study, modifications to the quantification setup and mobile phase of the HPLC system used to measure NO 2 -concentrations in solution achieved complete separation of the signal peak of NO 2 -from the front breakthrough and increased the sensitivity to nM levels (> 2 nM). This technical improvement would allow for more accurate quantification of NO 2 -in biological samples. Our detection limit was lower than the 30 nM achieved by another HPLC technique (Smith et al. 2002) , the 10 nM by flow-injection analysis (Kleinbongard et al. 2006) , and the 100 nM by electron spin resonance (Minakata et al. 2004) , and is comparable to the 1 nM limit reported using reduction chemiluminescence or another HPLC technique . Our results clearly demonstrated that complete separation of the NO 2 -signal from the sleeve of the front breakthrough led to significantly higher plasma NO 2 -levels and indicated the importance of the present conditions for accurate quantification of the signal.
We found here that the degree of NO 2 -contamination during sample processing is not a serious problem in comparison to our previous findings on NO 3 -contamination (Ishibashi et al. 2000a ). In particular, NO 2 -contamination from laboratory ware was virtually negligible except if using ultrafiltration units. We carefully selected a vacuum blood-sampling tube for minimum contamination according to our previous experience (Ishibashi et al. 2000a ), however it is still worth noting that many sampling tubes available for clinical use are contaminated with both NO 3 -and NO 2 -to varying degrees (Tsikas et al. 1997; Ishibashi et al. 2000a) . Fig. 7 . Arterio-venous differences in NO 2 -concentration in rabbit plasma. NO 2 -levels evaluated before (A) and 30 sec after (B) intravenous administration of NaNO 2 (500 nmoles/kg) in 6 rabbits (2.8 ± 0.1 kg). Open circles: Data of individual rabbits, closed circles: group mean ± S.E.M. values. Arterial, Arterial blood; Venous, Venous blood. **p < 0.01 (paired t-test), compared with arterial blood levels. Increases in NO 2 -levels in both arterial and venous blood after NaNO 2 injection were significant ( p < 0.01), however, marks denoting significance are not included to simplify the graphic presentation. One reason for the low level of contamination during sample handling in our protocol may be the avoidance of glassware known for persistent contamination (Ishibashi et al. 2000a; Smith et al. 2002) . Problems can be encountered during deproteinization to remove proteins and large particles before loading of samples (plasma) on the HPLC-Griess and other systems. This procedure is necessary, however, to protect the column and to avoid pressure build-up in the system. Ultrafiltration units are commonly used for deproteinization; however, such units are a potential source of significant NOx (not only NO 3 -, but also NO 2 -) contamination (Ishibashi et al. 2000a; Smith et al. 2002) . Although NO 2 -contamination below 30 nM was reported with some units (Smith et al. 2002) , precise determination of NO 2 -at nM level requires even lower detection limits. Our study found the lowest contamination with the Centrisart I unit, in agreement with a previous report (Tsikas et al. 1997) . However, the level was not negligible and might vary among units, leading to inaccurate evaluation. An alternative is the use of methanol for deproteinization. This study showed that methanol per se contains low levels of NO 2 -, and was associated with the lowest increase in NO 2 -. We therefore recommend methanol as the best option for deproteinizing samples at present. Samples in one experimental series or from one individual should be treated at the same time to avoid varying degrees of NO 2 -contamination.
Contamination of NO 2 -from the environment is time-dependent and can be serious. To minimize such contamination, we recommend restricting sample contact with the atmosphere using gas-tight ware wherever possible. We found that repeated vortexing of samples, with opening of tube caps to exchange air of the headspace before every vortex, did not increase NO 2 -levels significantly, However, this kind of vigorous agitation should be kept to a minimum to avoid any risk of atmospheric contamination. It is advisable to use sample containers that have minimal headspace for the same reason, and one should be more cautious when samples are handled in an environment nearby heavy traffic or a high density of factories. Furthermore, the use of flame or fire originating from liquid or gaseous fuel nearby may cause heavy contamination and preclude accurate evaluation (personal communication from a technical staff member of Eicom, Kyoto).
The same issue of atmospheric contamination should be considered for all solutions used in the HPLC-Greiss system. Wide and long bottle openings (mobile phase and Griess reagent) may increase NO 2 -levels, and hence the baseline absorbance value; this may negatively deflect the spectra for samples of significantly lower NO 2 -concentrations. Our countermeasure to this problem is restricting the inflow of the air to equal the outflow (rate of pumping), thereby avoiding unnecessary turbulence through the small injection needle and exchange of air in the headspace of the bottles.
By treating blood samples with the measures discussed above, we found clear arterio-venous differences in rabbit plasma NO 2 -levels. In contrast, an earlier report did not find a significant arterio-venous gradient in plasma NO 2 -levels sampled from human brachial artery and antecubital vein (Lauer et al. 2001) . Based on our findings, this discrepancy may be attributable to NO 2 -noise arising from contamination during complex sample handling (use of solutions containing NaCl and citrate, and ultrafiltration units). Indeed, we already reported higher NO 2 -levels in human arterial blood from the ascending aorta than in venous blood from the right atrium , and this agreed with another report evaluating human blood samples from brachial artery and antecubital vein (Gladwin et al. 2000; Cannon et al. 2001 ). In addition, the arterio-venous gradient was more prominent when NO 2 -, as well as NO itself by using NOR1, a NO releasing agent (Kato et al. 1996) , was administered. The possible significance of such a gradient is under debate. One suggestion is that NO 2 -supplies NO for the peripheral micorcirculation, which is rich in deoxyHb and therefore able to reduce NO 2 -to NO via nitrite reductase activity .
A previous report indicated that plasma NO 2 -decreased more rapidly when exogenously administered NO 2 -was incubated with venous blood than with arterial blood (Wennmalm et al. 1993) . Consistent with this finding was the demonstration that coexistence of deoxyHb (hypoxia) and nitrite generates NO (Deem et al. 2007; . NO may contribute to steady-state hemodynamics by activating guanylate cyclase in vascular smooth muscle, and the fate of the NO could be oxidation to NO 2 -or NO 3 -. However, no increase in NO 2 -was observed here in venous plasma. It is reported that NO under this circumstance could be stabilized as nitrosohemoglobin, leading to a decrease in plasma NO 2 - (Kruszyna et al. 1987) . The possible reaction of NO with deoxyHb to form iron-nitrosyl-hemoglobin, a highly stable adduct , would contribute to the decrease.
Extremely high doses of NO 2 -(10 mg/kg body weight of NaNO 2 , corresponding to 145 μ moles/kg body weight) decrease blood pressure in anesthetized animals (Blood and Power 2007) , although the dose used in our study (500 nmoles/ kg body weight) was not sufficient to cause such an effect. If the balance between NO generation and scavenging capacity of oxygenated hemoglobin is a determinant of NO availability for vasodilation (Deem et al. 2007 ), the small amount of NO from lower NO 2 -levels would not necessarily decrease blood pressure. In this case, conditions such as inhibition of nitric oxide synthase may be required for development of vasodilation from the smaller doses of NO 2 - (Rifkind et al. 2007 ) administered in the present study.
In conclusion, for accurate determination of NO 2 -in biological samples, care should be taken to minimize possible contamination from laboratory ware, especially ultrafiltration units, although the degree may be much less of a problem than that for NO 3 -determinations. Potential atmospheric contamination should be avoided also. A slight gradient in arterio-venous NO 2 -levels was detected in the plasma of a small number of animals when these cautions were carefully observed.
